FDAnews
www.fdanews.com/articles/186962-biogx-launches-six-ce-mark-tests-for-antibiotic-resistance-and-meningitis

BioGX Launches Six CE-Mark Tests for Antibiotic Resistance and Meningitis

May 24, 2018

BioGX expanded its BD Max molecular diagnostics platform with six CE Mark diagnosis tests for meningitis and antibiotic resistance.

The six new tests can diagnose viral meningitis HSV/VZV, bacterial meningitis NSH, bacterial meningitis ELGBS, carbapenem resistance KNO, carbapenem/colistin resistance VGM and vancomycin resistance.

With the expansion, the BD Max system now comprises eleven tests, with an additional ten planned for the second half of 2018.

View today's stories